Mechanism of TRAIL reversing multidrug resistance of human gastric adenocarcinoma SGC7901/ADR cells
Haibing SUN,Kaiguang ZHANG,Qin LI,Yingling LIU,Si CHEN
DOI: https://doi.org/10.3969/j.issn.1002-266X.2017.13.003
2017-01-01
Abstract:To investigate the influence of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on multidrug resistance gene (MDR1), multidrug resistance-associated protein (MRP1), anti-apoptotic gene Bcl-2 and pro-apoptotic gene Bax in human gastric cancer SGC7901/ADR cells and to explore the possible mechanism of TRAIL reversing multidrug resistance of gastric cancer.Methods The drug sensitivity of SGC7901/ADR cells and their parent cells SGC7901 to doxorubicin, vincristine and cisplatin was detected by MTT assay.The mRNA expression of MDR1, MRP1, Bcl-2, Bax gene of SGC7901/ADR and SGC7901 cells was detected by real-time fluorescence quantification PCR.SGC7901/ADR cells were treated with different concentrations of TRAIL (10, 50, 100 ng/mL).The real-time fluorescence quantification PCR and Western blotting were used to measure the expression of MDR1, MRP1, Bcl-2, Bax mRNA and protein of various genes in different treatment groups and the blank control group.Results MTT assay for drug sensitivity test showed that, compared with SGC7901 cells, the IC50 of SGC7901/ADR cells to doxorubicin, vincristine and sisplatin was significantly increased (P<0.01 or P<0.05).Compared with SGC7901, the expression levels of MDR1, MRP1, Bcl-2 mRNA in SGC7901/ADR cells were significantly increased, but the expression of Bax mRNA was decreased (all P<0.01).The mRNA and protein expression levels of MDR1, MRP1 and Bcl-2 in SGC7901/ADR cells were down-regulated by TRAIL, and the expression of pro-apoptotic protein Bax mRNA was up-regulated.Compared with the blank control group, there were statistically significant differences (all P<0.05).Conclusion TRAIL may down-regulate the expression of MDR1, MRP1, Bcl-2 and up-regulate the expression of Bax to promote the apoptosis of gastric cancer drug-resistant cells, and reverse multidrug resistance of gastric cancer drug-resistant cells.